Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Metformin With Simvastatin for Men With Prostate Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by Baylor College of Medicine
Sponsor:
Information provided by (Responsible Party):
Nicholas Mitsiades, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT01561482
First received: March 20, 2012
Last updated: March 27, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to find out whether the two drugs used in the study, metformin and simvastatin, can slow down the speed of rise of prostate specific antigen (PSA) or stop its rise or even bring the level down.

Recently, scientists noticed that men who take metformin to treat their high blood sugar or simvastatin to treat their high cholesterol are less likely to develop prostate cancer. Also, scientists found that, when these drugs are used in preclinical studies, they can slow down the growth of the prostate cancer cells. This study will try to find out whether these drugs can actually slow down the growth of prostate cancer in men.


Condition Intervention Phase
Prostate Carcinoma
Drug: Metformin
Drug: Simvastatin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label Study Of Metformin In Combination With Simvastatin For Men With Prostate Carcinoma And A Rising Serum Prostate-Specific Antigen Level After Radical Prostatectomy And/Or Radiation Therapy

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment. [ Time Frame: 6 months after subject start of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to protocol-specified event for men treated with the combination of metformin plus simvastatin. [ Time Frame: From treatment initiation till disease progression (assessed up to 5 years) ] [ Designated as safety issue: No ]
  • Pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus simvastatin. [ Time Frame: From treatment initiation till disease progression (assessed up to 5 years) ] [ Designated as safety issue: No ]
  • Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels. [ Time Frame: From treatment initiation till disease progression (assessed up to 5 years) ] [ Designated as safety issue: No ]

Estimated Enrollment: 37
Study Start Date: January 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metformin, Simvastatin

Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.

They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study.

Drug: Metformin
Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
Other Name: Glucophage
Drug: Simvastatin
The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
Other Name: Zocor

Detailed Description:

Men who participate in this study will take both metformin and simvastatin every day. Both drugs are pills and can be taken at home.

Subjects will be asked to take metformin and simvastatin until metastasis from their prostate cancer appears or until their PSA has doubled from what it was before they started the study.

Primary Objective:

To define the efficacy, as measured by an improvement in PSA doubling time (PSADT) at 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.

Secondary Objectives:

  1. To define the time to protocol-specified event for men treated with the combination of metformin plus simvastatin.
  2. To describe the pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus simvastatin.
  3. To describe the associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The study population will consist of subjects who have undergone primary therapy (prostatectomy or primary radiation) for biopsy-proven adenocarcinoma of the prostate and now have biochemical-only recurrence.

  1. Ability to understand and the willingness to sign a written informed consent document.
  2. Male 18 years or older.
  3. Histologically or cytologically confirmed diagnosis of prostate cancer.
  4. Biochemical recurrence following prostatectomy or radiation to the prostate, defined as at least 3 PSA rises, with each PSA determination at least 4 weeks apart, and each PSA value greater than or equal to 0.2 ng/mL.
  5. PSA must be less than 50 ng/mL at study entry.
  6. Screening PSA greater than or equal to 0.5 ng/mL for men who had a prostatectomy. Prior treatment with neoadjuvant, adjuvant, or salvage radiation therapy is allowed, again, with screening PSA greater than or equal to 0.5 ng/mL required for eligibility.
  7. Screening PSA greater than or equal to 1.0 ng/mL above their postradiation nadir for men who were treated with primary radiation therapy (external beam and/or brachytherapy). Men who had primary radiation therapy followed by salvage prostatectomy are eligible if screening PSA is greater than or equal to 0.5 ng/mL.
  8. PSA doubling time between 3 and 36 months.
  9. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
  10. Subjects must have normal organ and marrow function as defined below:

    * Leukocytes greater than or equal to 3,000/mcL * Absolute neutrophil count greater than or equal to 1,500/mcL * Hemoglobin greater than or equal to 10 g/dL * Platelets greater than or equal to 100,000/mcL * Total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance or calculated greater than or equal to 60 mL/min/1.73 m2 for subjects with creatinine clearance or estimated creatinine levels above institutional glomerular filtration rate (eGFR) normal * Creatine phosphokinase (CPK) less than or equal to the institutional upper limit of normal

  11. Ability to swallow the study drugs.
  12. Life expectancy of at least 12 months.
  13. Subjects should agree to avoid grapefruit juice which is a major inhibitor of CYP3A4.

Exclusion Criteria:

  1. Evidence of metastatic disease on imaging studies.
  2. Need for treatment with any conventional modality for prostate cancer (surgery, radiation therapy, and hormonal therapy).
  3. Prior hormonal therapy for recurrent prostate cancer (hormonal therapy given in a neoadjuvant or adjuvant setting and greater than 6 months before entry is acceptable).
  4. Prior chemotherapy for prostate cancer.
  5. Treatment within the last 30 days with any investigational drug.
  6. Radiation therapy within prior 6 months.
  7. Known hypersensitivity to metformin or statins.
  8. Subjects who need to take CYP3A4 inhibitors, such as cyclosporin, sirolimus, tacrolimus, verapamil,danazol, gemfibrozil, ketoconazole, or macrolide antibiotics (e.g., azithromycin, clarithromycin, erythromycin)will be excluded. Prior use of these agents is acceptable, as long as they are stopped at least a week prior to study entry.
  9. Subjects who need to take CYP3A4 inducers, such as phenobarbital, dexamethasone, carbamazepine,phenytoin, rifampicin, or non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine,etravirine) will be excluded. Prior use of these agents is acceptable, as long as they are stopped at least a week prior to study entry.
  10. Prior history of rhabdomyolysis.
  11. Prior history of lactic acidosis.
  12. Any history of myocardial infarction in the past 12 months.
  13. HIV-positive status.
  14. Subjects who consume more than 3 alcoholic beverages per day.
  15. Subjects with serious intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or other nonmalignant medical or psychiatric illness that is uncontrolled or whose control may be jeopardized by the complications of this therapy or may limit compliance with the study requirements (at the discretion of the investigator).
  16. Subjects diagnosed with or treated for another malignancy within 2 years prior to study enrollment or previously diagnosed with another malignancy and still having any evidence of residual disease. Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  17. Subjects currently treated with metformin or a statin or who have been treated with metformin or a statin in the past 6 months are ineligible for this study.
  18. Subjects who have taken 5a-reductase inhibitors (finasteride or dutasteride), saw palmetto, or PC-SPES within the last 6 weeks are ineligible for this study. Subjects taking other herbal supplements, vitamins, or other alternative medications are eligible for this study as long as they were started more than 2 months prior to study entry, have remained on a stable regimen, and will remain on a stable regimen for the duration of participation on this study.

Men of all races and ethnic groups are eligible for this trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01561482

Contacts
Contact: Nicholas Mitsiades, M.D., Ph.D 713-873-2010 mitsiade@bcm.edu

Locations
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Nicholas Mitsiades, MD, PhD         
Sub-Investigator: Benjamin L Musher, MD         
Sub-Investigator: Martha Mims, MD, PhD         
Sub-Investigator: Garret Lynch, MD         
Sub-Investigator: Anita Sabichi, MD         
Ben Taub General Hospital Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Nicholas Mitsiades, MD, PhD         
Sub-Investigator: Martha Mims, MD, PhD         
Sub-Investigator: Benjamin Musher, MD         
Michael E. Debakey Veterans Affairs Medical Center Recruiting
Houston, Texas, United States, 77030
Sub-Investigator: Teresa Hayes, MD, PhD         
Sponsors and Collaborators
Nicholas Mitsiades
Investigators
Principal Investigator: Nicholas Mitsiades, MD, PhD Baylor College of Medicine
  More Information

Publications:

Responsible Party: Nicholas Mitsiades, Assistant Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT01561482     History of Changes
Other Study ID Numbers: H-28936
Study First Received: March 20, 2012
Last Updated: March 27, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Baylor College of Medicine:
Prostate carcinoma
Prostate cancer
Prostate Specific Antigen
PSA
Metformin
Simvastatin
Radiation therapy
Prostatectomy

Additional relevant MeSH terms:
Carcinoma
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Prostatic Diseases
Urogenital Neoplasms
Metformin
Simvastatin
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 19, 2014